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Abstract
Problem: The CDC estimates one person every 20 minutes every day acquires an HPVrelated cancer. Kentucky’s HPV associated cancer burden is among the highest in the nation.
Adolescent HPV vaccination rates in Kentucky are far below HealthyPeople 2020 goals. Barriers
are multifaceted and include provider, patient and system barriers. The AFIX model is an
evidenced based quality improvement program that addresses key provider barriers. The USPSTF
findings identify a gap in the literature related to AFIX methods to improve rates of adolescent
vaccines.
Objectives: The purpose of this study was to evaluate the effects of an intervention using
the AFIX model and provider education focusing on the HPV vaccine as cancer prevention. Goal:
To evaluate provider knowledge & attitudes of the HPV vaccine and evaluate the effects of
provider education on vaccine rates. Specific Aims: 1. Evaluate frequency of use of CDC Talking
Points (rubric) 2. Evaluate changes in vaccination with use of rubric.
Methods: Utilizing the Assessment Feedback Incentives eXchange (AFIX) model, this
quasi-experimental pilot research project included four phases: a retrospective chart review to
establish baseline rates of HPV vaccination and a provider survey to identify barriers and
facilitators (Phase 1), an educational intervention focused on presenting the HPV vaccine as
cancer prevention (Phase 2), a process/outcome evaluation (Phase 3&4) to assess use and
feasibility of the CDC talking points rubric and an outcome evaluation to assess any change in
vaccine uptake.
Primary outcome variable: adolescents age 11-17, with no prior history of the HPV
vaccine receiving at least one dose.
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Results: 63 of 100 medical records reviewed met inclusion criteria. 79% of adolescents
received one dose of the HPV vaccine at a well-child visit. Only 34% received dose 2, and only
8% received dose 3. Significant demographic findings: older adolescents and non-Hispanics were
less likely to initiate HPV vaccine. Provider survey results revealed the most commonly reported
barrier at 80% was the HPV vaccine not being required for school entry. Participation in the
Vaccines for children (VFC) program was the most commonly reported facilitator at 82%. The
post-intervention process evaluation revealed 50% of the providers changed the way they
presented the HPV vaccine to parents. None of the providers used the CDC rubric and the most
common barrier was not having a copy to refer to. Two-thirds of the providers felt uptake of the
vaccine had increased since the 2-dose series introduced. Only 83% offer vaccine to females &
males 100% of the time. None of the providers feel the vaccine is accepted 100% of the time.
Summary/Implications: At 79%, the proportion of adolescents at HealthFirst Bluegrass
age 11-17 with one dose of the HPV vaccine was above the statewide average of 58%. The
proportion with 2 and 3 doses were on par with national averages, but were still below
benchmark. Because the baseline rates were just below the 80% goal and the provider surveys
revealed the school requirement barrier, the PI chose to shift the focus to a policy intervention at
the school level. Using a CDC drafted school nurse letter to parents of adolescents, the PI
proposed a new version of the 5th grade letter to be sent to all Fayette county incoming middle
school students. The current letter only lists the 2 state required vaccines (Tdap, MCV) and not
the third ACIP recommended HPV vaccine. Given the recent change in the ACIP
recommendation to a 2-dose regimen for young teens, this provides a prime opportunity to
promote the HPV vaccine to Fayette county middle school students and their parents.
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Running head: USE OF THE AFIX MODEL TO IMPROVE ADOLESCENT HPV
Use of the AFIX Model to Improve Adolescent HPV Vaccination:
A Pilot Research Project
Introduction
Rates of Human Papillomavirus (HPV) vaccination in Kentucky (KY) are below the
national average. Because of the identified link between provider recommendation and increased
rates of HPV vaccination (Smith, Stokley, Bednarczyk, Orenstein, & Omer, 2016), providerbased interventions such as the successful Assessment, Feedback, Incentives and Exchange
(AFIX) program should be implemented at the local level. AFIX is a quality improvement
program used to raise immunization coverage levels, reduce missed opportunities to vaccinate,
and improve standards of practice at the provider level (Centers for Disease Control &
Prevention, 2015). The AFIX program is an evidence-based intervention developed by the
Centers for Disease Control and Prevention (CDC) which gained recognition after immunization
coverage levels in public clinics in Georgia increased from 40% to 91% between 1986 and 2001.
Since 1996, this intervention has become a national model program to improve immunization
rates (LeBaron et al., 1997). The Community Preventive Services Task Force (CPSTF), a branch
of the United States Department of Health and Human Services (US-DHHS), “strongly
recommended” assessment and feedback methods such as AFIX in 1999, 2008, and 2015. The
task force’s regularly updated systematic review of the literature supports the use of the AFIX
model. Specific gaps in the literature identified by the CPSTF include measuring the
effectiveness of the AFIX program on adolescent vaccines (CPSTF, 2015). This provides
additional support for this pilot practice improvement project.

The following manuscript will include background information on both the HPV disease
epidemiology and the historical rates of the HPV vaccine. Additionally, a summary of a focused
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integrative literature review provided the evidence base for the chosen AFIX design and the
methods of this pilot research project.

The overall objectives and specific aims of the study

were based on HealthyPeople 2020 and 2016 Healthcare Effectiveness Data and Information Set
(HEDIS) measures for the HPV vaccine. The phases of methodology include a retrospective
chart audit, a baseline provider survey and educational intervention, and an outcome evaluation.
Specific study barriers and facilitators will follow the chart audit results and data analysis.
Finally, the practice and policy implications and areas for future research will conclude the
manuscript.

Background
According to the CDC, nearly 39,000 HPV associated cancers occur annually.
Approximately 23,000 cases are women and 19,000 are men. Of the HPV-associated cancers,
cervical cancer is the most prevalent in women, and oropharyngeal cancers are the most prevalent
in men. Nearly 90% of cervical and anal cancers, 70% of oropharyngeal, vaginal and vulvar
cancers, and 60% of penile cancers are HPV associated (CDC, 2016). The direct link between
HPV and cancer led to the development of the Human Papillomavirus Quadrivalent (Types 6, 11,
16, 18) Vaccine, Recombinant, approved in 2006. Additionally the Human Papillomavirus
Bivalent (Types 16 and 18) Vaccine, Recombinant was approved in 2009, and the Human
Papillomavirus 9-valent Vaccine, Recombinant was approved in 2014 (U.S. Food & Drug
Administration, 2016).

Kentucky has some of the highest rates of HPV associated cancers in the United States.
Specifically, Kentucky’s oropharyngeal cancer incidence rates rank first in men and third in
women. Vaginal and vulvar cancer incidences in KY rank first and second, respectively. Penile
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cancer incidence in Kentucky is second highest in the nation. Lastly, among the most common
HPV related cancer, cervical, Kentucky ranks 7th highest in incidence (CDC, 2016). Primary
prevention methods such as the HPV vaccine can reduce this disease burden.

In 2006, the HPV vaccine was approved by the U.S. Food and Drug Administration
(FDA) and the national Advisory Committee on Immunization Practices (ACIP) recommended
the vaccine be administered to females age 11-24. The HPV vaccine originally approved was a
three dose series with doses at zero, two, and six month intervals. In 2009, the vaccine was
further approved and recommended for administration to adolescent males age 9-26. Most
recently in October of 2016, the Quadrivalent and 9-valent vaccines were approved for a reduced
two- dose series with the second dose administered six to twelve months after dose one.

Since 2006, the uptake and compliance rates in adolescents have increased slowly, but the
vaccines continue to be underutilized. HPV continues to have lower uptake than the TetanusDiptheria-Pertussis (Tdap) and Meningicoccal vaccines (MCV). NIS-teen data from 2015 reveal
that Kentucky ranks 32nd in the nation in Tdap rates with 84% of adolescents age 13-17 with > 1
dose Tdap, 22nd in the nation in MCV rates with 79% with > 1 dose MCV, and only 57.4% of
females and 34.8 % males with > 1 dose HPV. Additionally, the most recent CDC NIS-teen data,
released in August of 2016 reveals that Kentucky ranked 47th of 50 states for 2015 in completion
of the series or > 3 doses of HPV vaccination in males, with a rate of only 17.1%. Females with >
3 doses are nearly double at 36.2%, and with > 2 doses 42.7% (Reagan-Steiner et al., 2016). The
disparity between rates of Tdap, MCV and HPV reveal missed clinical opportunities since all
three can be given at the same 11-12 year old well child visit. Methods to increase the uptake of
the HPV vaccine have been reported in the literature.
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Evidence base for Intervention
The AFIX program has its roots in the public health clinics of Georgia. In order to
increase coverage levels to achieve national immunization goals, the Georgia Department of
Public Health initiated a statewide program in 1986 that consisted of annual assessments of
immunization records at its public health clinics. Feedback was given to clinic providers and
their staff who then devised their own interventions to improve vaccination rates. Program
incentives included awards and rankings of clinics by coverage level as well as poster
presentations by successful clinics at annual immunization meetings. Other successful strategies
included coordinating with Women, Infants, and Children (WIC) Food and Nutrition Service,
conducting reminder/recall phone activities, and providing performance feedback to nursing
staff. Resulting from these combined efforts were immunization coverage levels in Georgia
public clinics increasing from 40% to 91% between 1986 and 2001. This intervention has
become a national model program to improve immunization rates (CDC, 2014).
LeBaron (1997) sought to investigate the marked increase in vaccination rates noted over
an 8-year period. He investigated the methods used and the outcomes to compare to national
averages. From 1988 – 1994 LeBaron was able to show that while Georgia’s vaccination rates
rose from 53% to 89%, the national average from the National Health Interview Survey (NHIS)
database rose from 53% to only 60% showing that the AFIX intervention was effective. The
CDC chose to adopt the Georgia model and recommend its use to all states. In 1999, LeBaron
expanded his research further to include other states and cities using the AFIX model. He was
able to show in four states (Colorado, Iowa, Louisiana and Missouri) and two large cities
(Boston and Houston) how use of the AFIX model led to vaccine rate improvements on par with
Georgia at five percentage points per year or a total average increase of 20% over four years.
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Appraisal of Evidence
Over the past several years as the focus on low rates of HPV vaccination has increased, a
few studies correlating the AFIX model with adolescent vaccine rates have been conducted.
An appraisal of the evidence was performed by compiling a synthesis table of the studies (see
Table 2). These studies were important in elucidating the need for the proposed provider AFIX
intervention. Common provider identified barriers such as time to educate, parental resistance
and difficulty in discussing HPV as an STI were identified in four of the studies (Bruno et
al.,2014; Bynum et al., 2014; Ferrer, H., Trotter, C., Hickman, M., & Audrey, S. , 2014; Hull et
al., 2014). Perhaps the strongest evidence was the common theme of provider as facilitator in
two of the level 1 studies (Jeudin et al., 2014; Rambout et al., 2014) and two other level 4 and 5
studies (Reiter et al., 2014; Thomas, Strickland, Diclemente, & Higgins, 2013). Lastly, there is
sufficient evidence supporting the use of the AFIX model to improve rates of adolescent HPV
vaccination. Five total studies ranging from levels 2-7 all show statistically significant rate
changes after implementation of an AFIX model at the provider level (Gilkey, Moss, et al., 2014;
LeBaron et al., 1997; LeBaron et al., 1999a; Moss, Reiter, Dayton, & Brewer, 2012a;Perkins et
al. ,2015) (see Table 2).
Based on a review of the available literature, there is evidence to suggest that
implementation of provider interventions, such as the AFIX model, could improve uptake of the
HPV vaccine in adolescents. Part of the HealthyPeople 2020 goals is to have at least 50% of
both public and private vaccine providers implement a method to measure their vaccination
coverage. The public sector is mandated to do this because they receive funds or vaccine
directly from the government. Vaccines for children (VFC) providers have mandated visits with
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Comprehensive Clinic Assessment Software Application (CoCASA) reports with rates of
immunization used as feedback.
Purpose
The purpose of this project was to evaluate the impact of a provider-focused educational
intervention focusing on HPV vaccine as cancer prevention. Primary outcome variables were 1)
adolescents age 11-17 with no prior history of the HPV vaccine initiating the vaccine at a wellchild visit and 2) proportion of providers utilizing the CDC Talking Points.
This pilot research project was conducted at an urban health clinic in the southern United States.
The specific goal of the project was to increase rates of HPV vaccination among adolescents at
the clinics through provider education and use of the AFIX quality improvement model. Specific
Aims: 1. Evaluate frequency of use of CDC Talking Points (rubric) 2. Evaluate changes in
vaccination with use of rubric. Hypothesis: 1. Educational session will increase use of rubric
from 0 to 80% 2. Use of the rubric will increase initiation rates to 80%.
This pilot research project aimed to assist a Health Resources and Services Administration
(HRSA) granted primary care organization in the Southeast. Improving rates of adolescent HPV
vaccination could fulfill the HealthyPeople 2020 goal of 80% vaccination rates among
adolescents. Quality improvement measures such as improving vaccine rates help to fulfill
requirements of HRSA grantees.
Methods/Study Design
This quasi-experimental pilot research project design included four phases: a retrospective
chart review (Phase 1), an educational intervention (Phase 2), a process evaluation (Phase 3), and
an outcome evaluation (Phase 4).
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The retrospective chart review was conducted on patient charts from December 15, 2015
to February 15, 2016. Additionally, a post-intervention retrospective chart review was planned
from December 15, 2016 to February 15, 2017. All providers volunteering to participate in the
face-to-face educational in-service signed an informed consent prior to participation. The HPV
vaccine is ACIP recommended at the 11-12 year old well child visit or on a catch-up schedule.
Based on a power analysis of increasing rates from 57% to 80%, the goal was to review at least
100 medical records. The data collected during the chart review included patient age, gender,
race, and insurance type. Other data included was if counseling on the vaccine was provided and
by whom, if the vaccine was offered, if it was accepted/declined/deferred by the patient, if the
series was initiated, and if it was completed. No patient identifying information was included.

All pediatric and family providers practicing in the clinic were asked to participate in the
survey and educational session. An email with a survey cover letter was sent to all providers in
the clinic. The survey was administered via REDCap, and all survey results were kept
anonymous. For the educational session, the PI asked for volunteers and distributed informed
consents at a provider staff meeting prior to the scheduled educational session. Participation in
the educational session was also voluntary.

Research Procedures
For the retrospective chart review, the PI assessed the FQHC clinic practices regarding
HPV vaccine rates. Specifically, the PI examined 100 electronic medical records to assess the
proportion of HPV vaccines that were administered to adolescents between 11-17 years of age.
The clinic provided a list of patient medical record numbers for patients ages 11-17 that
presented to the FQHC clinic for routine well-child exams (V20.2) between December 15, 2015
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and February15, 2016. No one other than the PI had access to the list of medical record
numbers, and the list was kept in a locked file cabinet drawer in the clinic. Only the PI had this
key. Once the electronic medical records were accessed, the list of medical record numbers was
destroyed per the clinic’s HIPAA policy. Participants included all males and females age 11-17
with encounter for a well-child visit with vaccines (ICD-9 codes V20.2, V04.89, V05.8 and CPT
code 90649). Patients were excluded if they initiated the HPV vaccine before the current 11-17
year old well-child visit.

Survey/ Educational Intervention

Before initiating the educational phase, an online REDcap survey and cover letter on the
HPV vaccine was distributed to all pediatric providers at the clinic via email. An educational
session on the CDC Talking Points evidence based rubric was presented at several lunchtime
staff meetings to those providers volunteering to participate between December 1st and 15th and
completing the informed consent. This educational session was part of the Incentives component
of the AFIX program.

Providers were then asked to trial use of the CDC script in their

adolescent visits.

Process/Outcome Evaluation

To determine feasibility and sustainability of the intervention, anonymous provider
surveys sent via REDcap were completed voluntarily two months after the intervention
(educational session). Providers were asked to report on whether they are using the CDC talking
points, and if so, how often; if not, they were asked to disclose the barriers (see Appendix G).
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The final planned step of this pilot research project was a measurement of the proportion
of HPV vaccination rates in 11-17 year olds two months after the intervention. This was to be
completed using the same electronic medical record review process and inclusion/exclusion
criteria to determine baseline rates of HPV vaccination. One hundred to 200 medical records
were originally proposed for the outcome evaluation from December 15, 2016- February 15,
2017. The quantity of records (100-200) was based on the original power analysis to increase
the proportion from 57% to 80%. Because the baseline rates were 79%, a revised power analysis
indicated that 600 records would be needed to detect a significant change in vaccine rates given
the goal of 80%. In two months time 600 well visits for 11-17 year olds would not be generated.
Therefore, the outcome evaluation of vaccine rates was not completed.
Data collection/analysis
All data was collected in Redcap, a secure online research database. The database was
analyzed using statistical SPSS software version 23.0 using crosstabs with frequencies,
percentages and chi-squared analysis. Significant findings were reported at p > .05.
Results
Retrospective medical record review of 100 electronic medical records revealed the
following descriptive data: 63 met inclusion criteria of no prior history of the HPV vaccine;
79% (n=50) initiated/accepted the HPV vaccine; only 34% (n=17) received the 2nd dose, and
only 8% (n=4) completed the series with the third dose. Uptake of the HPV vaccine was broken
down into the following demographic categories: age, gender, race, ethnicity and insurance
coverage (see Table 1). Significant findings included age and ethnicity. Adolescents accepting
the HPV vaccine were significantly younger than those who declined to initiate vaccination
(M=13.1, SD=2.0 versus M=14.5, SD=2.1; p =.024). Non-Hispanics (69%) were significantly
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less likely (p=0.012) to initiate the HPV vaccine compared with Hispanics (92%). Gender, race
and insurance status were non-significant.
Baseline surveys were distributed to 14 pediatric providers, and 11 providers
participated. Questions were posed related to the provider practice of offering the HPV vaccine
and provider perception of HPV vaccine uptake. Additional survey questions evaluated provider
identified barriers and facilitators to uptake.
A majority of providers or 63% (n=7) report offering the HPV vaccine 100% of the time
to females and males, 27% (n=3) offer females and males the vaccine 75-99% of the time, and
just 10% (n=1) offer it 50-74% of the time. Provider perception of vaccine uptake by gender
was more varied. Only 27% (n=3) of providers reported that females initiated HPV vaccine 7599% of the time, whereas the remaining 73% (n=8) reported female uptake as 50-74%. Male
uptake of the vaccine was reported as lower, with only 27% (n=3) reporting 75-99%, 44% (n=5)
reporting 50-74%, 18% (n=2) reporting 25-49%, and <10% (n=1) reporting 0-24% of male
uptake (see Tables 2-5).
The most commonly reported barrier by just over 80% (n=8) of providers was not having
the HPV vaccine as a requirement for middle school entry. Most frequent provider reported
facilitators were participating in the VFC program 82% (n=9) and having the time to educate
patients about the HPV vaccine 73% (n=8).
Provider survey results revealed that 50% of providers (n=3) changed the way they
presented the vaccine, although none of them reported using the CDC Talking Tips. The most
commonly reported barrier was not having a copy of the CDC Talking Tips available. Lastly, as
discussed previously, the outcome evaluation of a change in vaccine rates was not completed due
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to baseline proportion of 79% with a power analysis of > 600 EMRs needed to detect a
statistically significant change to the goal of 80%.
Discussion
Major findings
The retrospective record review revealed that 79% of the FQHC’s adolescents age 11-17
with no prior history of the HPV vaccine initiated/accepted the vaccine at a well-child visit. This
was just below the goal of 80% based on HealthyPeople 2020 goals. Uptake of doses 2 and 3
were significantly lower at 34% and 8% respectively. Significant demographic correlations
included both age and ethnicity. The younger the patient the more likely they were to accept dose
1 of the HPV vaccine. This finding is potentially based on the increase in well child visits at age
11-12 for adolescents to get the school required physical and Tdap and MCV immunizations.
This study’s results are different from Bynum et al. (2014) and Reiter et al. (2014) who found
that older adolescents age 13-14 were more likely to initiate the vaccine. Additionally, Hispanic
patients were more likely to accept /initiate the vaccine than non-Hispanic patients. This mirrors
the 2015 NIS-teen data revealing Hispanic males & females having higher uptake of the HPV
vaccine over non-Hispanics (CDC, 2016). Baseline provider survey results highlighted the
barrier of the HPV vaccine not being required for school entry, as well as providers being less
likely to offer the vaccine to males over females. The post-intervention survey revealed that
50% of respondents (n=6) changed the way they present the HPV vaccine to patients. None of
the providers used the CDC rubric specifically, and the most commonly reported barrier to this
was not having a copy of the rubric available.
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Study Barriers/Facilitators
Barriers encountered were mostly logistical in nature. Initially, the PI planned to have an
educational session (the study intervention) for all pediatric providers at one or two staff
meetings. The pediatric providers work at two main clinics and seven school-based clinics. This
group only meets every other month, and the adult providers (not part of the study population)
are also at those meetings. Additionally, as part of an accreditation process, this FQHC had an
Operational Site Visit (OSV) scheduled in early December, so all staff meetings for the month
were cancelled.
Consequently, the intervention phase was several either individual or small group
meetings to present the CDC Talking Points rubric. This shift in methodology actually became a
facilitator because of the small group or individual environment. Several of the providers were
able to verbalize their frustrations at the HPV vaccine not being required for school entry as a
significant barrier to the vaccine’s uptake. Additionally, the PI was able to review the new
Vaccine Information Statement (VIS) with the 2-dose ACIP regimen just released December 2nd,
2016. A few providers were unaware of the 2-dose series until it was presented. The providers
at the seven school based clinics were also not together for a meeting during the proposed
educational phase of the study. Several, but not all, of the school based pediatric providers
completed the online survey. Rather than a face to face educational intervention, the PI
distributed the CDC Talking Points rubric and the CDC slide-set to the seven school based
providers via email as they were not available in the last two weeks of December because of
School Clinic closings.
Other facilitators of this pilot study were guideline based and patient education/ outreach
based. At the time of the study intervention (mid-December), the new CDC/ ACIP
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recommendation for a 2-dose regimen for 11-15 year olds was released. The new VIS, dated
12/2/2016, was distributed to providers and nurses, but practice dissemination had not yet
occurred. This provided an additional incentive for the PI to encourage providers to recommend
the new 2-dose HPV series to adolescents. Additionally, the VFC program distributed large,
stand-up life size posters of a boy and a girl with the logo “If there were a vaccine against cancer
wouldn’t you give it to me?” At the time of the provider intervention, the two main clinics of the
FQHC had these life-size posters in their lobbies. Only one of the school clinics had the posters
displayed.
Practice Implications
Based on the results of the medical record review and provider survey, several practice
and policy recommendations can be made. Specifically, the provider survey highlighted the
perception that males initiate the HPV vaccine less often than females. Implications include the
need to make a concerted effort targeting males especially since their rates of cancer are
comparable (CDC, 2016). This perception could lead to providers’ hesitation to strongly
recommend the HPV vaccine to males as well as females. The objective data from the
retrospective record review revealed that males had a slightly higher uptake over females,
possibly suggesting recommendation to females should be stronger. Other demographic data
that could influence practice habits relate to ethnicity and insurance status. Non-Hispanics and
those with Medicaid or no insurance were less likely to initiate the vaccine. The latter group is
the population eligible for free vaccine from the VFC program. According to the provider
survey of patient facilitators, awareness of the VFC program ranked lowest with only 36% (n=4)
of providers believing their patients were aware of the availability of free vaccines. This
combination of data indicates a practice gap for promoting patient awareness of the VFC
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program. Another possible area for practice change is EMR prompts or reminders. Only one
provider indicated that EMR prompts/ reminders influenced HPV vaccine rates.
Upon review of patients missing the HPV vaccination, a check of the Kentucky
Immunization Registry (KYIR) found several records of either HPV vaccine initiation or
completion. These records had not been either scanned into the EMR or manually entered as
historical into the immunization record. A process recommendation to the clinic manager,
CMAs and nurses will be that a designated person check the KYIR weekly for all scheduled well
child visits to ensure up to date records.

Policy Implications

According to Bynum et al. (2014) survey results of provider-identified barriers can be
utilized in development of interventions to increase vaccination rates. The provider survey
results from this study reveal that the lack of a school mandate is a significant barrier. Efforts
nationwide to school mandate the HPV vaccine have been poorly received. Unfortunately, in
Kentucky there have been several failed legislative attempts for HPV vaccine education or a
school mandate for adolescents to obtain the HPV vaccine (National Council of State
Legislatures, 2017). To date, only two states and the District of Columbia have a school
mandate for the HPV vaccine. While legislation mandating this may not be realistic at this point,
an alternate strategy would be to include an endorsement by both the school nurses and
principals on the school letters sent home to all incoming middle school students. The CDC as
well as the National Association of School Nurses (NASN) have the same adolescent vaccine
letter template (see Appendix F) posted as a policy initiative for school districts (CDC, 2016;
National Association for School Nurses, 2015). The PI proposed that this letter replace the
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current school letter distributed to all rising 6th graders. The letter currently in use only lists the
two adolescent vaccines required by Kentucky Statute (Tdap and MCV), but omits the
CDC/ACIP recommended HPV vaccine. A key component of the proposed letter is the focus of
the HPV vaccine as cancer prevention. Additional strength to this letter will be the new 2-dose
regimen CDC/ACIP approved December 2, 2016 for adolescents age 11-15. The PI amended
the CDC letter to include the 2-dose regimen, as the online school letter template did not reflect
this change. This letter was proposed to the school district health coordinator in a meeting on
February 23, 2017. The district health coordinator approved the nurse and principal letter for
distribution this spring and summer to all incoming middle school students.

Summary

The burden of HPV associated cancers in Kentucky is among the highest in the country.
Additionally, the rates of HPV vaccination continue to be far below the nationwide averages.
Although Kentucky’s initiation rates are low, this pilot study revealed an FQHC with initiation
rates near HealthyPeople 2020 goals. Provider identified barriers and facilitators influenced the
practice and policy implications. The most commonly reported barriers at just over 80% (n=9)
were the lack of a school mandate for the HPV vaccine and the fact that patients are unlikely to
return for doses 2 and 3. Objective data supported the providers’ subjective data as only 34% of
patients returned for dose 2 and only 8% for dose 3. Based on this, a policy initiative to increase
all three ACIP adolescent vaccines was proposed to the Fayette county district health coordinator
in late February. A nurse letter, principal letter and text message reminders for all 3 ACIP
recommended adolescent vaccines will be initiated this spring.
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Future research could assess the impact of the school based campaign as well as the new
2-dose series. Because of the provider reported barrier of returning for doses 2 and 3, a followup study at the FQHC could include an assessment of completion rates with the new 2-dose
regimen versus completion rates with the 3-dose regimen.
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Table 1. Demographic characteristics by HPV vaccination (N=63)
Total sample

Initiated HPV vaccination
p

n = 63
Age

Yes

No

(n =50)

(n =13)

13.1 (2.0)

14.5 (2.1)

.024*

>.05

Sex
Male

29 (54%)

22 (72%)

7 (18%)

Female

34 (46%)

28 (84%)

6 (22%)

White

19 (30%)

14 (74%)

5 (26%)

Black

37 (60%)

32 (87%)

5 (13%)

Other

6 (10%)

3 (50%)

3 (50%)

Hispanic

39 (62%)

27 (69%)

12 (31%)

Non-Hispanic

24 (38%)

23 (92%)

1 (8%)

Private

5

5 (100%)

0 (0%)

Medicaid

46

36 (78%)

10 (22%)

Uninsured

11

9 (82%)

2 (18%)

Race
>.05

Ethnicity
.012*

Insurance

*significance at level p <.05

19

>.05
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Table 2. Provider Survey Results (n=11) offer vs. accept/initiate HPV vaccine
100%

75-99%

50-74%

25-49%

How often offer HPV vaccine to females 11-17

7

3

1

0

How often offer HPV vaccine to males age 11-17

7

3

1

0

How often do females accept/initiate

0

3

8

0

How often do males accept/initiate

0

3

5

2
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Table 3. Provider reported practice facilitators (n=11)
Practice facilitators

Total

Participates in the VFC program

9

11

Have the time to educate patients about the HPV vaccine

8

11

Reminders within the EMR for the HPV vaccine

1

11

Clinic uses a form that prompts CDC recommended vaccines

2

11
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Table 4. Provider reported practice barriers (n=11)
Yes

Total

2

11

Practice not adequately reimbursed for HPV vaccine

1

11

HPV vaccine not stocked or in low supply

0

11

I do not have the time to discuss HPV vaccination
during visits

22
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Table 5. Provider reported patient barriers (n=11)
Unaware of the risks of HPV

4

11

Think the cost of the HPV vaccine is too high

0

11

Worried about long-term safety of the vaccine

0

11

Unlikely to return for 2nd and 3rd dose

7

11

Unlikely to get vaccine because it is not required for

8

11

1

11

school entry
Concerned about the pain associated with the vaccine
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Table 6. Relevant literature
Citation

Conceptu
al
Framewo
rk

Design/
Method

Sample/Settin
g

Major
Variables
Studied and
Their
Definitions

Outcome
Measureme
nt

Data
Analysis

Findings

Level
of
Evid
ence

Quality of
Evidence:
Critical
Worth to
Practice

(Ferrer
et al.,
2014)
Ferrer,
H. B.,
Trotter,
C.,
Hickma
n, M., &
Audrey,
S.
(2014).
Barriers
and
facilitat
ors to
HPV
vaccinat
ion of
young
women
in highincome
countrie
s: a
qualitati

Critical
Appraisal
Skills
Program
me
criteria
for
evaluatin
g
qualitativ
e research

Qualitati
ve
systemati
c review
and
evidence
synthesis

Sample: 41
Studies were
eligible if
qualitative
research
methods
(interviews,
focus groups,
observations)
or open-ended
questions in
questionnaires
were used to
explore views
and behaviors
related to
decisionmaking of
HPV
vaccination of
young women.

Qualitative
&
descriptive,
so no
independent/
dependent
variables
quantified

Used a socioecological
model to
provide a
framework
for
understandin
g how
decisions of
stakeholders
at different
levels of the
model may
affect access
of the HPV
vaccine for
young
women.

Data
pertaining to
the
methodology
and context,
including
study and
participant
characteristic
s of each
primary
study, were
extracted and
entered into
an excel
spread sheet
by one
reviewer
(HF).

Qualitative
findings:
providers were
generally
favorable
towards HPV
vaccine; some
felt
uncertainty
about
the safety
profile of the
vaccine and
that early
vaccination
may mean
protection
would not be
maintained to
the age of
sexual debut;
Healthcare
professionals
suggested that
parents with
general ‘anti-

V

Strengths:
Comprehensi
ve review of
a range of
perspectives
resulting in a
more
complete
picture in
relation to
decisionmaking for
HPV
vaccination
The method
of using
qualitative
synthesis
within a
socioecologi
cal
framework
enabled
facilitators
and barriers
to

24
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vaccination’
beliefs were
unlikely to
make positive
HPV vaccine
decisions;
evidence
presented here
suggests that
some
healthcare
professionals
avoided
conversations
with parents
about the HPV
vaccine if they
perceived this
to be culturally
inappropriate.

ve
systemat
ic
review
and
evidenc
e
synthesi
s. BMC
Public
Health,
14, 700.
doi:
10.1186
/1471245814-700

(Rambo
ut et al.,
2014)
Rambou
t, L.,

None
mentione
d

Systemat
ic review
with data
analysis

Sample:
Twenty-two
studies
including
8079 females
aged 9–26

Selfidentified
barriers and
facilitators to
receiving the
HPV vaccine

Data
abstraction
form was
developed a
priori and
pilot-tested
25

Descriptive
synthesis of
abstracted
data was
completed
for all

The most
commonly
reported
facilitators
were perceived
benefit of the

be identified
in relation to
different
stakeholders
Limitations
Studies not
published in
English were
excluded and
the findings
reported
therefore
may be
subject to
English
language
publication

I

SR of
RCT’
s and

Strengths:
First
systematic
review to
isolate views
of adolescent
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Tashkan
di, M.,
Hopkins
, L., &
Tricco,
A. C.
(2014).
Selfreported
barriers
and
facilitat
ors to
preventi
ve
human
papillo
mavirus
vaccinat
ion
among
adolesce
nt girls
and
young
women:
A
systemat
ic
review.
Preventi
ve
Medicin

years in North
America,
published
between
2008 and 2011
Inclusion
criteria:
Qualitative or
quantitative
studies of selfreported
barriers to the
HPV vaccine
in adolescents
and young
women age 926 (US &
Canada only)

by two
reviewers.
Two
reviewers
then
performed all
data
abstraction in
duplicate.
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included
studies with
respect to
study
characteristic
s, study
outcome
results, and
study
quality.
Heterogeneit
y among
studies
precluded
metaanalysis.

vaccine and
receiving a
recommendatio
n from a
healthcare
provider, which
were each
reported in six
of the studies.
endorsement by
influential
others, such as
parents and
health care
providers,
appear to be
important
factors in
prompting
vaccination

cohor
t
studie
s

girls and
young
women with
respect to the
acceptability
of HPV
vaccination.
Limitations:
the pooling
of data from
small
samples of
participants
with
differing
characteristic
s thus
limiting the
ability to
assess
whether
diverse
interventions
may be
needed for
various
subgroups of
young
females.
Applicable
to practice
setting
because of
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e, 58,
22-32.
doi:
10.1016
/j.ypme
d.2013.1
0.009
(Hull et
al.,
2014)
Hull, P.
C.,
William
s, E. A.,
Khabele
, D.,
Dean,
C.,
Bond,
B., &
Sanders
on, M.
(2014).
HPV
vaccine
use
among
African
America
n girls:
Qualitati

theme of
influence of
endorsement
by
healthcare
provider

Dissemin
ation of
Innovatio
ns Theory

Design:
crosssectional
observati
onal
design,
Method:
Focus
groups
and
interview
s

Sample:
African
American
girls ages 11–
18 (N=34) and
their mothers
(N=31),
broken into
market
segments
based on
daughter's
vaccination
status and
mother's
intent to
vaccinate

No IV or DV
because
qualitative
study design

Comprehensi
ve review of
transcription
data of focus
groups and
interviews

Setting:
convenience
sampling

27

Four
research
assistants
were trained
during two
90-min
sessions to
code the
transcript
data,
including
how to use
Atlas.ti
qualitative
analysis
software to
create and
assign codes
and extract
quotes

Barriers to
vaccination
included no
recommendatio
n from
healthcare
professional
Decision
influencers for
both mother &
daughters also
included a
provider
recommendatio
n
Recommendati
ons from
mothers:
Message from
trusted source;
Recommend
together with

VI

Strengths:
This is the
first
published
study to
identify
specific
market
segments
related to
HPV vaccine
and to report
on
formative
qualitative
data aimed at
comparing
the
Undecided
segment
to those who
have
received or
rejected the
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ve
formativ
e
research
using a
participa
tory
social
marketi
ng
approac
h.
Gynecol
ogic
Oncolog
y, 132,
S13S20.
doi:
10.1016
/j.ygyno
.2014.01
.046
(Bynum
et al.,
2014)
Bynum,
S. A.,
Staras,
S. A.,
Malo, T.
L.,

other
preteen
vaccines;
Information
about
safety/side
effects;
Statistics on
cancer and
mortality

none
mentione
d

Using
Dillman
Multiphase
recruitme
nt
approach:
Surveys
mailed

Physicians
eligible for
study
inclusion
included those
who saw 25 or
more 9- to 17year-old girls
in the past

Independent
variables:
physician
demographi
cs (age,
gender,
practice
specialty)

5-point
Likert scales
were used in
survey

28

Multivariable
logistic
regression
was used to
model the
probability of
recommendin
g
the HPV

34% of
physicians
recommended
vaccination for
girls in the
early (9-10
years)
vaccination age
group.

vaccine.
Limitations:
self-reported
data and
convenience
sampling
Application:
Data further
supports the
influence of
provider
recommenda
tion for the
vaccine

VI

Strengths:
large
random
sample size
Limitations:
data were
selfreported,
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Giuliano
, A. R.,
Shenkm
an, E., &
Vadapar
ampil, S.
T.
(2014).
Factors
associate
d With
Medicai
d
provider
s'
recomm
endation
of the
HPV
vaccine
to lowincome
adolesce
nt girls.
J
Adolesc
Health,
54(2),
190-196.
doi:
10.1016/
j.jadohe
alth.201

between
10/2009
and
04/2010
to a
random
sample of
800
Floridabased
physician
s serving
Medicaid
-enrolled
adolescen
ts. Data
were
analyzed
in 2013
A multiitem
survey,
adapted
from a
previous
national
study
of HPV
vaccinati
on among
physician
s, was

year and had a
primary care
specialty. Of
the 800
mailed
surveys, 485
were
completed and
returned. Of
those, 52 did
not meet
eligibility
criteria. The
final study
sample
included 433
physicians.
The overall
response
rate was
68.3%

Dependent
variables:
rates of
recommendi
ng HPV
vaccine

vaccine to
adolescent
girls aged 917.
All analyses
were
conducted in
2013 using
SPSS 20.0.
Statistical
tests were
two-tailed,
with alpha
level of .05
and 95%
confidence
interval (CI)
for odds
ratios (OR).
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74% of
physicians
recommended
vaccination for
11- to 12-yearold adolescent
girls.
86% of
physicians
recommended
HPV
vaccination to
adolescent girls
aged 13-14.
Discomfort
discussing
STIs with
parents was
negatively
associated with
HPV vaccine
recommendatio
n for all
groups,

which may
have
introduced
recall and
reporting
bias.
Feasibility
of use in
practice:
Results of
provider
identified
barriers can
be used to
aid in
developmen
t of
intervention
s to increase
vaccination
rates
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3.08.006

(Bruno
et al.,
2014)
Funding:
NIH/NC
I grant
Bruno,
D. M.,
Wilson,
T. E.,
Gany,
F., &
Aragone
s, A.
(2014).
Identifyi
ng
human
papillom
avirus
vaccinati
on
practices

used to
assess
barriers
related to
HPV
vaccine
recomme
ndation
None
mentione
d

Crosssectional
survey of
randomly
selected
primary
care
providers

Sample: 552
providers
were
identified and
a random
sample of 120
was generated
64%- Peds.
19% internists
17% - family
practitioners
Setting:
Brooklyn,
New York
between
November
2010 and
January
2012.

Independent
variables:
Provider
demographi
cs

Survey used
Likert scale
responses

Dependent
variables:
Whether or
not HPV
vaccine was
offered;
identified
barriers

Data were
manually
entered into
an access
database by a
research
assistant and
quality
control was
performed by
the principal
investigator
to find and
address any
potential data
entry
problem.
Analysis was
performed
using IBM
SPSS
Statistics®
ver-

Inclusion
30

34%of
respondents
reported that
they routinely
offered HPV
vaccine to their
eligible
patients. 70%
of physicians
reported that
the lack of
preventive care
visits for
patients in the
eligible age
group limited
their ability
to recommend
the HPV
vaccine and
70% of those
who reported
this barrier do
not routinely

VI

Strengths:
identifies
several
potential
opportunitie
s for
intervention
s that could
lead to
increased
HPV
vaccination.
Limitations:
Results are
all selfreported, so
possibility
that
respondents
reported
socially
desirable
responses.
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among
primary
care
provider
s of
minority
, lowincome
and
immigra
nt
patient
populati
ons.
Vaccine,
32(33),
41494154.
doi:
10.1016/
j.vaccine
.2014.05
.058

criteria:
pediatricians,
family practitioners, and
internal
medicine
physicians
serving
neighborhood
s
identified
from the
American
Community
Survey as
having
large minority
populations
(greater than
30%) and
higher than
the average
rates of HPV
related cancer
cases
according to
the New York
State Cancer
Registry

sion 19.
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recommend
HPV vaccine.
most common
barrier
impeding them
from offering
the vaccine
was lack of
time to
educate parents
or patients
(66%).

Feasibility
of use in
practice:
Using the
identified
barrier of
not enough
time to
educate
parents/pati
ents can
assist with
intervention
s to increase
patient
education
(i.e. the
CDC HPV
fact sheet
for parents)
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(Thomas
et al.,
2013)
Funding:
Robert
Wood
Johnson
Foundati
on
Thomas,
T. L.,
Stricklan
d, O.,
Dicleme
nte, R.,
&
Higgins,
M.
(2013).
An
opportun
ity for
cancer
preventi
on
during
preadole
scence
and
adolesce
nce:

Health
Belief
Model
(HBM)

Descripti
ve crosssectional
design
Method:
surveys,
and
quantitati
ve
analysis.

Sample: 519
subjects (35%
response rate)
Inclusion
criteria:
parent or
primary
caregiver
responsible
for girls or
boys aged 9 to
13 years; had
to reside in the
counties of
interest, speak
and read
English, and
be at least 18
years of age.

Independent
variables: 4
constructs of
the HBM
Perceived
vulnerability
, perceived
severity,
perceived
benefits,
perceived
barriers

Likert scales

Descriptive
statistics
were
calculated for
all variables
t tests and
analysis of
variance F
tests for all
continuous
variables and
c2 tests for
all
categorical
variables.

Dependent
variables:
Intent to
vaccinate or
not
vaccinate
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343 (66.1%)
indicated that
they will not or
had not
vaccinated
their child,
169 (32.6%)
indicated that
they will or
had vaccinated
their child, and
7 (1.3%) did
not respond to
this question.
Focusing on
perceived
barriers and
benefits and on
parents’ level
of knowledge
about HPV,
healthcare
providers can
have frank
conversations
with parents in
order to
facilitate the
parents’
informed
decision
making.

VI

Strengths:
Large
sample
cohort study
with
focused
rural parent
population
Limitations:
Very low
response
rate with
telephone
survey
method, so
methods
were
changed to
paper &
pencil &
face to face
to increase
response
rates.
Feasibility
of use in
practice:
This study
is
particularly
useful for
providers in
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stopping
human
papillom
avirus
(HPV)related
cancer
through
HPV
vaccinati
on. J
Adolesc
Health,
52(5
Suppl),
S60-68.
doi:
10.1016/
j.jadohe
alth.201
2.08.011
CDC
NIS data
2013
Retrieve
d from:
http://w
ww.cdc.
gov/vacc
ines/who
/teens/va

a rural
practice
setting to
provide a
framework
from which
to design
intervention
s to
increase
rates of
HPV
vaccination

Design:
The NISTeen is a
randomdigitdialed
telephone
survey of
parents
and

Sample: 6,039
by landline
(59.5%) and
12,225 by cell
phone
(54.5%) had
adequate
provider data

Independent
variables:
Demographi
cs (age,
gender,
ethnicity,
incomelevel,
insurance
coverage)

Nationwide
HPV vaccine
rates:
1-dose= 57%
2-doses=47%
3-does=37%
Kentucky’s
rates:
1-dose= 47%
33

NA

Strengths:
Large
sample
national
survey with
provider
verified
vaccine data
included
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ccinatio
ncoverage
.html
http://w
ww.cdc.
gov/mm
wr/previ
ew/mm
wrhtml/
mm6329
a4.htm?s
_cid=m
m6329a
4_w#tab
3

guardians
of teens
13–17
years old;
in 2013,
it
included
data for
more than
18,000
adolescen
ts. The
telephone
survey is
followed
by
collection
of
vaccinati
on
records
from
clinicians
.
Method:
random
digit dial
(RDD)
listassisted
landline
and cellphone

2-doses=38%
3-does=26%
Dependent
variables:
Provider
verified
rates of
vaccination
from 2013

Top 5 reasons
parents did not
initiate
vaccine:
Lack of
knowledge=
15.5%
Not necessary=
14.7%
Safety
concerns=
14.2%
Not
recommended
=
13%
Not sexually
active=11.3%

Parental
reasons for
not
vaccinating

34

Weaknesses
: response
rates may
mean
incomplete
data

Implications
Kentucky is
nearly 10%
points
below the
national
level
NO
provider
recommend
ation is 4th
out of 5 on
the list of
barriers at
13%
reported
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sample
frame
CDC
HPV
statistics
Retrieve
d from:
http://w
ww.cdc.
gov/canc
er/hpv/st
atistics/s
tate/cerv
ical.htm

Data from
populationbased cancer
registries
participating
in the CDC’s
supported
National
Program of
Cancer
Registries or
NCI’s supported
Surveillance,
Epidemiology,
and End
Results
Program,
includes all
states meeting
USCS
publication
criteria for all
years 2006–
2010 and
covers
approximately
94.8% of the
U.S.
population.

Incidence of
HPV in
Kentucky 8.049.54 per
100,000
Nationwide
rates are
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NA

Implications
:
KY ranks in
the highest
tier of
cervical
cancer rates
in the US,
so programs
to increase
HPV
vaccine
rates are
validated
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(Jeudin
et al.,
2014)
ACS
grant
Jeudin,
P.,
Liverigh
t, E., del
Carmen,
M. G.,
&
Perkins,
R. B.
(2014).
Race,
Ethnicit
y, and
Income
Factors
Impacti
ng
Human
Papillo
mavirus
Vaccina
tion
rates.
Clinical
Therape
utics,
36(1),
24-37.

None
mentione
d

Systemat
ic review
of 124
reference
s ( NIS
data,
RCT’s)

Sample:
relevant
Englishlanguage
literature (124
sources) to
identify
current
vaccination
rates and
factors
associated
with vaccine
uptake.

Independent
variables:
age, gender,
ethnicity
Dependent
variables:
rates of
vaccine
initiation and
completion;
barriers and
facilitators to
vaccination

Systematic
review of
data
pertaining to
outcomes of
HPV vaccine
rates, and
identified
barriers and
facilitators

36

HPV
vaccination
recommenda
tion by a
health care
provider has
been shown
to increase
the
likelihood of
vaccination
up to 18-fold
(95% CI, 1–
23) and up to
90% of
females who
report
vaccination
also report
provider
recommenda
tion.

Provider
recommendatio
n is a key factor
in HPV
vaccination,
and minorities
are less likely
to report
receiving
recommendatio
ns for HPV
vaccination;
desire to
prevent cancer
was also a key
factor in
vaccination
rates

I

Strengths:
Systematic
review of
124
references
by 4
physicians
from Boston
University
and Harvard
Limitations:
The exact
methods of
data
extraction,
analysis and
synthesis
were not
described by
the authors
Feasibility
of use in
practice:
Because
provider
recommendtion is
crucial to
vaccine
uptake, and
each
provider
interacts
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doi:
10.1016
/j.clinth
era.2013
.11.001

(Gilkey,
Dayton,
et al.,
2014b)
Gilkey,
M. B.,
Dayton,
A. M.,
Moss, J.
L.,

with
hundreds to
thousands of
patients,
interventions
targeting
providers
such as
academic
detailing or
performance
improvement
continuing
medical
education
may be
effective
ways to
improve
vaccination
rates.
CDC’s
AFIX
model for
improvin
g
vaccinatio
n rates

Randomi
zedcontrolle
d trial

Sample:
randomly
assigned 91
primary care
clinics in
North
Carolina,
serving
107,443
adolescents, to

Independent
variables:
IV1 = inperson AFIX
consultation
IV2 =
webinar
consultation
IV3 = no

Primary
study
outcome was
5month
coverage
change for
Tdap,
meningococc
al vaccine,
37

x2 (Chisquared)
tests and
analysis of
variance
models were
used. To
analyze
intervention
effects at the

Among
adolescents
ages 11 to 12
years,
AFIX
consultations
increased
coverage
for the 3
vaccines in the

II

Strengths:
statistical
significance
found at the
5-month
follow-up in
the 2
intervention
arms
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Sparks,
A. C.,
Grimsha
w, A.
H.,
Bowling
, J. M.,
&
Brewer,
N. T.
(2014).
Increasi
ng
Provisio
n of
Adolesc
ent
Vaccine
s in
Primary
Care: A
Random
ized
Controll
ed Trial.
Pediatri
cs,
134(2),
E346E353.
doi:
10.1542
/peds.20

receive
1. no
consultation 2.
an in-person
or 3. webinar
AFIX
consultation.
Inclusion
criteria:
pediatric and
family
practice
clinics with
> 200 patients
ages 11 to
18 years with
active records
in the registry;

consultation
Dependent
variables:
Rates of
adolescent
vaccinations
at 5 mo.
Follow-up
and at 1 year

and HPV
vaccine
initiation
(>1dose,
female
patients
only); also
analyzed
coverage
changes for
other
vaccines at 5
months and
for all
outcomes at
1 year.

38

level of the
patient,
authors
performed
mixed-level
Poisson
regressions for
each
vaccine,
modeling the
change in
vaccine
coverage
between
baseline and
follow-up for
each age
group.

adolescent
platform at 5
months
In-person arm
rate increases:
Tdap (3.4%)
MCV (4.7%)
HPV (1.5%)
Webinar arm:
Tdap (3.6%)
MCV (4.4%)
HPV (1.9%)

adolescents 13
to 18 years,
AFIX
consultations
increased
vaccine
coverage at 5
months only for
the in-person
versus control
arms for HPV
vaccine series
completion
(0.7%).

Limitations:
no statistical
significance
found in
intervention
arms at 1year
may
indicate
that vaccine
providers in
the
intervention
arms were
able to
initiate,
but not
sustain,
quality
improvement
efforts
Feasibility
of use in
practice:
This study
has direct
correlation
to support
program
planning
using the
AFIX model
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13-4257

(Reiter
et al.,
2014)

secondary
data
analysis
of
publicly
available
data from
the NISTeen

analyzed
providerverified
vaccinati
on data
from the
2010–
2011
National
Immuniz
ation
SurveyTeen for
Hispanic
females
ages 13
to 17
years (n
=2,786).

Sample:
Hispanic
adolescent
females age
13-17; N=
2786
Setting: 20102011 NIS data
from the CDC

Independent
variables:
ethnicity,
age &
gender
Dependent
variables:
rates of
vaccination;
determinants
of
vaccination

Rates of
vaccination
as reported
by the NIS
data
Correlates of
HPV
vaccination
identified in
NIS data
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weighted
logistic
regression to
identify
correlates of
HPV vaccine
initiation

Healthcare
provider
recommendatio
n was one of
the
key
determinants of
HPV
vaccination
among
Hispanic
adolescent
females. HPV
vaccine
initiation was
60.9%,
completion was
36.0%, and
follow-through
was 59.1%.
Initiation
and completion
were more
common
among older
daughters and

IV

Strengths =
large cohort
(2736) of
respondents
Limitations
= focused on
Hispanic
population
Applicable
to practice
setting
because
provider
recommenda
tion was
again an
identified
key
determinant
to HPV
vaccine
initiation
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those whose
parents had
received a
provider
recommendatio
n to vaccinate
(all P < 0.05).
Spanishspeaking
parents were
more likely
to indicate lack
of provider
recommendatio
n (20.2% vs.
5.3%)
**(Moss
, Reiter,
Dayton,
&
Brewer,
2012b)
Moss, J.
L.,
Reiter,
P. L.,
Dayton,
A., &
Brewer,
N. T.
(2012a).

CDC’s
AFIX
model

A onemonth
immuniz
ation
competiti
on
among
federally
qualified
health
centers,
during
April
2010.
Participat
ion was

clinical
coordinators
from 17
federally
qualified
health centers
(serving 7827
patients ages
12–17) in
North
Carolina
participated in
a competition
to increase
uptake of
adolescent

Rates of
recommende
d adolescent
vaccines:
tetanus,
diphtheria,
and pertussis
booster;
meningococc
al conjugate;
and human
papillomavir
us.

Rates of
adolescent
vaccine
coverage
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Data
analyses
used SAS
Version 9.2
(Cary, NC).
Statistical
tests were
two-tailed
with a
critical alpha
of .05.

Vaccine uptake
increased over
the one-month
follow-up
period
(p < .001,
Table 2). Prior
to the
intervention,
31.1% (IQR,
13–33%)
of each clinic’s
adolescent
population was
up-to-date on
targeted

VII

Strengths:
A strength of
this
study is the
use of webbased
technology
to administer
the AFIX.
intervention
components.
While
studies have
shown that
the AFIX
program has
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Increasi
ng
adolesce
nt
immuni
zation
by
webinar:
A brief
provider
interven
tion at
federall
y
qualifie
d health
centers.
Vaccine,
30(33),
49604963.
doi:
10.1016
/j.vaccin
e.2012.0
5.042

open to
all of the
131
federally
qualified
health
centers
in the
state, and
18
clinics
opted to
participat
e in an
AFIX
webinar

vaccines

and nontargeted
vaccines, while
after the
intervention,
32.2% (IQR,
14–34%) was
up-to-date
(Chi-square =
27.34, p <
.001).

relatively
low costs],
employing
webinars and
emails
reduces the
costs
associated
with inperson visits.
Limitations:
did not have
a control
arm, as
this would
not have
been
acceptable to
the
community
partners;
however, the
use of an
instrumental
comparison
(nontargeted
vaccines)
allowed
authors to
treat clinics
as their own
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controls.

**(LeBa
ron et
al.,
1999b)
LeBaron
, C. W.,
Mercer,
J. T.,
Massou
di, M.
S., Dini,
E.,
Stevens
on, J.,
Fischer,
W. M., .
..
DesVig
nesKendric
k, M.
(1999).
Changes
in clinic
vaccinat

AFIX
model

Retrospe
ctive
examinat
ion of
clinic
vaccinati
on
coverage
data

Children aged
19 to 35
months
enrolled in
clinics in
localities that
had applied
the
intervention
for 4 years or
longer.

Four states
and 2 cities
that had
applied the
AFIX
intervention
for 4 years
or longer
were
identified.
The number
of clinic
records
reviewed
annually was
4639 to
18,000 in 73
to 116
clinics for
states, and
714 to 5276
in 8 to 25
clinics for
cities.

Change in
median clinic
coverage
rates, based
on the
primary (4-31) vaccine
series, with
comparison
to results of
the National
Immunizatio
n Survey.
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Authors used
same method
as in Georgia
Distribution
plot by rank
ordering all
clinics in a
locality by
coverage
rate, plotting
this
distribution
in deciles
and
determining
the median

Median clinic
coverage rose
in all localities:
Missouri, 44%
(1992) to 93%
(1997);
Louisiana, 61%
(1992) to 83%
(1997);
Colorado, 55%
(1993) to 75%
(1997); Iowa,
71% (1994) to
89% (1997);
Boston, Mass,
41% (1994) to
79% (1997);
and Houston,
Tex, 28%
(1994) to 84%
(1997). The
increase in
clinic coverage
exceeded that
of the general
population in 5

IV

Strengths:
Average
vaccine rate
increase of
5% over 4years was
very close to
the 6%
increase seen
in the
Georgia state
7 year study.
Demonstrate
s
reproducibili
ty of positive
effects

Limitations:
the clinics
measured
began
collecting
vaccination
data and

None
Examina Children
Vaccination
For the
**(LeBaron mentioned tion of
attending
coverage
period 1988
et al., 1997)
data
Georgia
rates
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LeBaron, C.
from
public clinics.
1994, 136
W., Chaney,
Georgia
004 Georgia
M.,
public
public clinic
ion
Baughman,
clinics,
vaccination
coverag
A.eL.,
Dini,
dosesrecords for
after
E.instituti
F., Maes,
administ
children 21
E.,onDietz,
ered
to 23 months
of
V.,measure
&
records,
of age were
Bernier,
R.
and
reviewed.
ment
(1997).
National
and
Impact
of
Health
feedbac
measuremen
Intervie
k in 4
t and
w
states
feedback
Surveys.
and 2 on
vaccination
cities.
coverage
ITS
Archivesin
public
based
of
clinics,
Pediatri
1988-1994.
cs &
Jama,
Adolesc
277(8),
ent 631635.
Medicin
e,
153(8),
879886.
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Basic
statistical
analysis
(medians,
ranges)

Median seriescompletion
rates at public
clinics rose
from 53% to
89%, while
localities
and
indexes
of in
was identical
underthe sixth. The
vaccination
average
annual
fell: missed
coverage
rise
opportunities
attributable to
theforintervention
simultaneous
was
+5
vaccination
percentage
(6% per
to 0%),
points
year
lost
contact
(Georgia, +6 for
than 12
permore
year).
months (14% to
1%), and first
vaccination
more than 1
month late
(19% to 8%)
In 1988,
vaccination
coverage of
children 24
months of age
in the National
Health
Interview
Survey (NHIS)
was 53%,
identical to
median public
clinic coverage
in Georgia; in
1993, NHIS
coverage was
60%, while
median public
clinic coverage
in Georgia was
90%,

IV

Study
shows
widespread
application
of the AFIX
program
using
the
with
AFIX model
measurable
before
the
increases
in
federal
vaccination
mandate was
in rates
place, so
had an
established
protocol
Applicable
to practice
setting
because
shows clear
vaccination
rate increase
using the
AFIX
program
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**(Perkins,
2014)
Perkins, R.
B., Zisblatt,
L, Legler,
A., Trucks,
E.,
Hanchate,
A.and
Gorin, S.S.
(2014).
Effectivenes
s of a
providerfocused
intervention
to improve
HPV
vaccination
rates in boys
and girls,.
Vaccine, In
press.

None
mentioned

RCT
Provider
-focused
intervent
ion that
included
repeated
contacts,
educatio
n,
individu
alized
feedbac
k, and
strong
quality
improve
ment
incentiv
es to
raise
HPV
vaccinat
ion rates
at two
federally
qualified
commun
ity
health
centers.

Sample: 13,
118 eligible
patients from
8 clinics
2 clinics and
4093 patients
randomly
chosen for
intervention
arm
Control arm
was remaining
6 clinics with
9025 eligible
patients

Assessment
of baseline
HPV vaccine
rate

HPV
Vaccination
rates of
patients age
11-21

Independent
variable:
Intervention
arm or nonintervention
arm

multivariable
logistic
regression,
controlling
for clustering
by practice
All analyses
were
performed
using Stata
Version
10.1.

Dependent
variable:
Number
initiating
HPV vaccine
and
completing
subsequent
dose due

During the
active period,
girls at
intervention
practices were
more likely to
initiate HPV
vaccination
than those at
control
practices (OR
1.6 95% CI
1.1–2.2), ,
differences
between
intervention
and control
practices did
not remain
significant in
the postintervention
period.
For vaccinenaïve boys, the
odds of
initiating HPV
vaccination
were similar at
intervention
and control
practices in the
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II

Strengths:
this study
demonstrates
the ability of
a providercentered
multicomponent
PI CME
intervention
to create
sustained
improvemen
t in HPV
vaccination
rates. All
practices
improved
over time,
especially
for boys, but
intervention
practices
demonstrate
d
improvemen
ts beyond
those seen in
control
practices
Limitations:
The dramatic
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preintervention
period. The
odds of vaccine
initiation
among boys at
intervention
compared to
control
practices rose
to 11 (95% CI
6.9–18) in the
transition
period, 11
(95% CI 6.9–
17) in the
active period,
and remained
elevated at 8.5
(95% CI 5.2–
14) in the postintervention
period

Interven
tions
included
six to
eight
sessions
conduct
ed over
approxi
mately
12
months.

improvemen
ts in HPV
vaccination
rates for
boys were
catalyzed by
the
availability
of statefunded HPV
vaccine for
boys during
the transition
period,
making the
effects of the
intervention
difficult to
distinguish
from the
effects of
increased
vaccine
availability
Applicability
to practice:
The authors
utilized the
AFIX model
for their
intervention
and achieved
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measurable
improvemen
ts in HPV
vaccine rates
in a large
population

Key Terms and Abbreviations:
AFIX = Assessment, Feedback, Information and Exchange

Tdap = Tetanus, diptheria and pertussis vaccine

CDC = Centers for Disease Control
CI = Confidence Interval
DV = Dependent variable
HPV = Human Papillomavirus
IV = Independent variable
ITS = Interrupted time series study
MCV = Meningicoccal vaccine
NIS = National Immunization Survey
RCT = Randomized controlled trial
SR = Systematic review
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Table 7. Level of Evidence Synthesis Table
1

2

Level I: Systematic
X
review (SR) or metaanalysis
Level II:
Randomized
Controlled Trial
(RCT)
Level III: Controlled
trial without
randomization
Level IV: Casecontrol or cohort
study
Level V: SR of
qualitative or
descriptive studies
Level VI:
Qualitative or
descriptive study
Level VII: Expert
opinion or consensus

X

3

4

X

X

5

6

7

X

X

X

8

9

10

11

12

X

X

X

X

13

X

X

Key to Synthesis table
1 - (Jeudin et al., 2014) 2 - (Rambout et al., 2014) 3 - (Gilkey, Dayton, et al., 2014b) 4 - (Perkins, 2014)
5 - (LeBaron et al., 1997) 6 - (LeBaron et al., 1999b) 7 - (Reiter et al., 2014)
8 - (Ferrer et al., 2014)
9 - (Bruno et al., 2014)
10 - (Bynum et al., 2014) 11 - (Hull et al., 2014)
12 - (Thomas et al., 2013) 13 - (Moss et al., 2012a)

47

USE OF THE AFIX MODEL TO IMPROVE ADOLESCENT HPV
Table 8. Evaluation Methods
Evaluation
Methods

Measures
(Level of
Measure)

Data
Source

Data
Collection
Plan

Timeline

Type of
Evaluation

Type of
Data
Analysis

Objective 1
To increase
numbers of
HPV
vaccination
among
adolescents
11-17
Specific
Aim 1:
80% of
providers
utilize
CDC rubric
when
presenting
the HPV
vaccine
Specific
Aim 2:
80% of
adolescents
initiate 3
dose HPV
series.

Proportion
of HPV
vaccination
in 11-17
year olds
(count)

EMR
Query

Pre intervention

Baseline
rates
(December
2015February
2016)

Outcome

Chi-square
analysis

Number of
provider
respondents
indicating
regular use
of CDC
rubric
(count)

Provider
Survey

Pre- and
postintervention
survey

December,
2016 –
February
2017

Process

Percentages
&
frequencies
Chisquared
analysis

Proportion
of HPV
vaccination
in 11-17
year olds
(count)

EMR
Query

Postintervention

Post
Intervention
rates
(December
2016 –
February
2017)

Outcome

Chi-square
analysis
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Appendix A. Chart Audit Tool
Study number:_______________
Gender:_____________________
Age:________________________
Race:_______________________
Insurance:___________________

At the patient’s 11-17 year old well-child visit, were the following documented:

Information

Yes

No

Comments

Was counseling
on the HPV
vaccine provided? By: ___ CMA
____NP/MD
Was the HPV
vaccine offered?
Patient’s response __ Accepted
__ Deferred
if vaccine was
__ Declined
offered
Was the HPV
vaccine series
initiated?
Was the vaccine
series initiated or
completed prior
to this visit?
Were the other
ACIP
recommended
vaccines (Tdap &
MCV) given?
Doses given (Y/N)? #1_________ #2__________ #3___________
On-time? Y/N
Y/N
Y/N
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Appendix B. Provider Survey/Questionnaire
Please answer the following questions by selecting the answer that best represents your experience as a provider:
1. How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old FEMALES?
100%
75-99%
50-74%

2.

25-49%
0-25%

How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old MALES?
100%
75-99%
50-74%

25-49%
0-25%

3. When offered, what percentage of your FEMALE patients accept HPV vaccination:
100%
75-99%
50-74%

25-49%
0-25%

4. When offered, what percentage of your MALE patients accept HPV vaccination:
100%
75-99%
50-74%

25-49%
0-25%

Which of these factors affect your decision to recommend the HPV vaccine in your current practice? Please select
all that apply:
Practice Facilitators
My practice participates in the Vaccines
for Children (VFC) program.
My clinic has reminders within the
EMR for HPV vaccination.
My clinic uses a form during well-child
exams that prompts for CDC
recommended vaccinations.
I have time to educate my patients about
HPV and the vaccine.
Other:

Practice Barriers
The HPV vaccine is not stocked or there is low
availability in my practice.
My practice is not adequately reimbursed for HPV
vaccine administration.
I do not have time to discuss HPV vaccination
during patient visits.
Other:

Continued on next page……
Which of these factors affect your decision to recommend the HPV vaccine in your current practice? Please select
all that apply:
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Provider Facilitators
I strongly recommend the HPV vaccine
to all eligible patients.
I have completed continuing education
regarding HPV and/or the HPV vaccine.
I am aware of the CDC/ACIP
recommendations for HPV vaccination.
Other:

Patient Facilitators
My patients have a good understanding
of the risks of HPV infection.
My patients/their parents believe that
they are at risk for HPV.
My patients have a belief in primary
prevention.
My patients are aware of the Vaccines
for Children (VFC) program and its
coverage.
My patients have positive peer/family
support regarding HPV vaccination.
Other:

Provider Barriers
I have concerns about the long-term safety of the
HPV vaccine.
I feel uncomfortable discussing a vaccine for a
sexually transmitted infection with my patients
and/or their parents.
I do not agree with the CDC/ACIP
recommendations for HPV vaccination.
Other:

Patient Barriers
My patients are unaware of the risks of HPV
infection.
My patients think the cost of the HPV vaccine is too
high.
My patients are worried about the long-term safety
of the HPV vaccine.
nd
My patients are unlikely to return for the 2 and
rd
3 dose of the vaccine series.
My patients are unlikely to get the vaccine because
it is not required for school entry.
My patients are concerned about the pain
associated with the HPV vaccine.
Other:

Please answer the following questions about the CDC/ACIP recommendations for HPV vaccination to the best of
your knowledge:
8. What is the recommended interval for HPV vaccination? Check all that apply
a. 0, 3, and 6 months
b. 0, 1-2, and 6 months
c. 0, and 6-12 months
d. 0, 6, and 9 months

Continued on next page…
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9. What is the ideal age of vaccination for males and females?
a. ages 11-12, can be given as early as 9
b. ages 13-15, can be given as early as 11
c. ages 9-13, can be given as early as 9
d. ages 15-18, can be given as early as 9
10. What are the recommendations for catch-up vaccination for males and females?
a. Catch-up for unvaccinated men and women ages 13-18.
b. Catch-up for unvaccinated men and women ages 13-21.
c. Catch-up for unvaccinated men ages 13-21 (and up to 26 for special populations), catch-up for women 13-26.
d. Catch-up for unvaccinated men ages 15-21 (and up to 26 for special populations), catch-up for women 15-26.

Comments: Please feel free to share any comments or ideas you have related to the HPV vaccine
recommendations for 11-12 year olds in your clinic…

THANK YOU FOR PARTICIPATING!
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Appendix C. CDC slide set on HPV vaccine

You are the Key
to HPV Cancer Preven on
Understanding the Burden of HPV Disease,
the Importance of the HPV Vaccine Recommenda on,
and Successfully Communica ng about HPV Vaccina on
Emily Messerli
DNP candidate
University of Kentucky College of Nursing
December2016
{Updated Nov 18, 2015)
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Appendix D. Provider talking tips rubric
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Appendix E – proposed 5th grade school letter with 6th grade health requirements (Principal)

Dear Parent/Guardian, Your student will be enrolling in the 6th grade next year and will need the following
on file prior to starting school. Per 902 KAR 2:060 a student cannot attend school without this
documentation.
1. A school Physical Examination is required for 6th grade entry.
(Done within one calendar year of enrollment. The KHSAA Sports Physical Form & Consent is a different
form and cannot be substituted.)
2. A current, updated Kentucky Immunization Certificate, including all previously required
immunizations and the following 6th grade requirements.
* One dose of Tdap regardless of interval since last dose of Tetanus-containing vaccine will be required
for students at 6th grade entry, with option of Td for individuals who cannot receive Pertussis-containing
vaccine.
* Two (2) doses Varicella or proof of history of Chicken Pox. (Proof of Chicken Pox (Varicella) disease in
lieu of immunization must now be in the form of a diagnosis of typical Varicella disease or verification of a
history of Varicella disease or Herpes Zoster disease by a healthcare provider.)
* One dose of Meningococcal vaccine (MCV) for 6th grade entry. The use of Meningococcal Conjugate
Vaccine is preferred, but Meningococcal Polysaccharide Vaccine (MPSV) may be used if the conjugate
vaccine is unavailable.
th

6 grade recommended vaccines:
•
HPV vaccine is recommended for preteens at age 11 or 12 to protect against cancers and
other diseases caused by HPV infection. Both boys and girls should receive 2 doses of HPV vaccine to
protect against these serious diseases. Your preteen should receive the second dose 6-12 months after
the first dose.
3. If your student is going to play sports in middle school, they will need a KHSAA Sports Physical Form
& Consent completed by you and your Healthcare Provider. The form is available online through
www.fcps.net
Please return your student’s forms as soon as you’ve had the appointment with your Healthcare Provider.
If you complete these requirements over the summer, please bring the forms to your student’s middle
school prior to the first day of school.
Thanks for your help with getting your student’s required 6th grade documentation turned in.

_______________________
School Principal
Date
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Appendix F. School Nurse Letter
[INSERT NURSE NAME], School Nurse
[INSERT SCHOOL ADDRESS]
[INSERT CURRENT DATE]
Dear Parent or Guardian:
As your child’s school nurse, I want to remind you of the importance of getting your son or daughter
vaccinated before they go back to school this fall. Vaccines are the best way you can protect your child
from a number of serious diseases, including cancers caused by HPV.
As you are making your back-to-school checklist for your preteen, I encourage you to make sure your
sons and daughters get all the vaccines that are recommended for them. Schedule your child’s
appointment today to ensure they are up-to-date on the vaccines they need. The Centers for Disease
Control and Prevention (CDC) and the Advisory Committee on Immunization Practices recommend your
son or daughter receive the following vaccines:


Quadrivalent meningococcal conjugate vaccine is recommended for preteens at age 11 or 12 for
protection against bacteria that cause meningococcal disease, a very serious illness which can
lead to death in as little as 48 hours. A second shot is recommended for teens at age 16 to
continue providing protection.



HPV vaccine is recommended for preteens at age 11 or 12 to protect against cancers and other
diseases caused by HPV infection. Both boys and girls should receive 2 doses of HPV vaccine to
protect against these serious diseases. Your preteen should receive the second dose 6-12
months after the first dose.



One dose of Tdap vaccine is recommended for preteens at age 11 or 12 to continue providing
protection against tetanus, diphtheria, and pertussis (whooping cough).



Preteens and teens should also get the flu vaccine every year, ideally as soon as the vaccine is
available.

Kentucky requires Meningococcal and Tdap for school entry; to learn more about state immunization
requirements, go to: www.immunize.org/laws.
Protect your preteen and talk with your child’s clinician about what vaccines they need. You may also
contact me with any questions. I can be reached at [PHONE NUMBER] and I am in my office [INSERT
OFFICE HOURS FOR VISITS]. I can also provide you with additional resources about vaccination and
other health topics for the preteen and teen years. To learn more about adolescent vaccines, please visit
CDC’s Vaccines for Preteens and Teens website at www.cdc.gov/vaccines/teens.
Sincerely,
[INSERT NAME OF SCHOOL NURSE]
Your School Nurse
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